Compare Funko Inc (FNKO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Funko Inc vs Mesoblast Limited — how do they compare? Funko Inc trades at $6.54 (market cap $363.97M), while Mesoblast Limited trades at $14.26 (market cap $1.75B). The key difference: Mesoblast Limited is far larger — about 4.8× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Funko Inc for 33 Days and Mesoblast Limited for 14 Days on average.
| FNKO | MESO | |
|---|---|---|
Market Cap | $363.97M | $1.75B |
Volume | 1,422,651 | 239,027 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.10 | $20.96 |
52-Week Low | $2.81 | $13.19 |
Typical Hold Time | 33 Days | 14 Days |
Enterprise Value | $584.62M | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Funko (FNKO) trades at $6.31, up 3.27% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 EBITDA guidance to $105M. Revenue declined to $908M in 2025 but shows stabilization with 2026 projections at $933M. Analyst consensus is mixed with 42.9% buy ratings and $7.58 price target, representing 20% upside potential.
Investment opportunity centers on turnaround execution with improving margins and debt reduction. Key risks include negative net income margins, competitive pressures in collectibles, and sensitivity to consumer discretionary spending. The stock offers value with low P/S of 0.38x but requires sustained profitability improvement to justify higher valuations.
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
